When fever and imaging suggest infection but every targeted test returns empty-handed, the clinician is left holding suspicion without proof — a familiar impasse in the care of immunocompromised and transplant patients. Next-generation sequencing reframes the diagnostic question itself, shifting from 'is this specific pathogen here?' to 'what is actually present?' by reading the entire microbial landscape at once. This technological turn, embodied in platforms capable of identifying hundreds of fungal and bacterial species simultaneously, represents a quiet but consequential evolution in how m
NGS Technology Transforms Uncertain Infections Into Actionable Diagnoses
Moving from suspicion toward specificity in the diagnostic dead end
Mark
Why does it matter that NGS asks "what organism is present" instead of "is this organism present"? Aren't both questions trying to find the same thing?
Mimi
Not quite. The first question assumes you already know what you're looking for. The second question doesn't assume anything. When a patient is immunocompromised and their symptoms could mean ten different infections, you can't test for all ten pathogens one by one—it takes too long, costs too much, and you might miss the right answer anyway. NGS lets you look at everything at once.
Mark
But if you're looking at 534 fungal species at the same time, doesn't that create noise? How do you know which organism actually caused the infection?
Mimi
That's where the enrichment strategy matters. The technology uses probes to pull out microbial DNA before sequencing, so you're not drowning in human DNA. You get deep coverage of the organisms that are actually there. And clinicians still use clinical judgment—they look at the patient's symptoms, their risk factors, their imaging. The test gives them the full picture instead of forcing them to guess.
Mark
You mentioned immune response testing alongside pathogen identification. Why is that the missing piece?
Mimi
Because finding an organism doesn't tell you whether the patient can fight it. An immunocompromised person might have a pathogen present but no ability to mount a response. Knowing both—what's there and whether the patient can respond—changes the treatment strategy entirely. It's the difference between treating a symptom and treating a person.
Mark
This sounds like it would be expensive and slow.
Mimi
It's faster than running ten separate tests that all come back negative. And for a transplant patient or someone with cancer who's running out of time, getting a definitive answer in days instead of weeks—or never—has real value. The cost question is fair, but so is the cost of treating the wrong infection or missing the right one.
Mark
What happens to patients who fall through the cracks—the ones without access to this kind of testing?
Mimi
That's the harder question. This technology exists in specialized labs serving transplant centers and major medical institutions. If you're in a resource-limited setting or a rural hospital, you're still working with conventional tests. That gap matters.
O Pulso
- Patients with ambiguous fevers, negative cultures, and inconclusive imaging face a diagnostic dead end that conventional single-pathogen testing was never built to escape.
- Immunocompromised individuals, transplant recipients, and cancer patients are disproportionately trapped in this gap, where overlapping symptoms and low-burden infections evade standard molecular tests entirely.
- Hybrid-capture NGS technology enriches microbial DNA from patient samples and sequences the full pathogen landscape simultaneously, detecting 534 fungal species and 154 acid-fast bacterial species in a single assay.
- Pairing pathogen identification with immune functional assays — measuring whether a patient can actually mount a defense — gives clinicians two answers where they previously had none.
- The diagnostic trajectory is shifting from reactive guesswork toward personalized, comprehensive infectious disease management grounded in actionable molecular evidence.
When fever and imaging suggest infection but every targeted test returns empty-handed, the clinician is left holding suspicion without proof — a familiar impasse in the care of immunocompromised and transplant patients. Next-generation sequencing reframes the diagnostic question itself, shifting from 'is this specific pathogen here?' to 'what is actually present?' by reading the entire microbial landscape at once. This technological turn, embodied in platforms capable of identifying hundreds of fungal and bacterial species simultaneously, represents a quiet but consequential evolution in how medicine navigates uncertainty — moving from educated guesswork toward something closer to genuine clarity.
A patient arrives with fever, suggestive imaging, and markers of inflammation — but cultures return negative and targeted tests find nothing. For the clinician, the suspicion of infection is strong; the evidence to act on it is not. This diagnostic impasse is especially common among immunocompromised patients, transplant recipients, and those undergoing cancer treatment, whose symptoms blur across conditions and whose infections may be too subtle or unexpected for conventional tests to catch.
Traditional molecular diagnostics are built around a narrow question: is this specific pathogen present? When no one has guessed the right organism to test for, or when the infection exists at low levels, the answer comes back negative — and the clinician is no closer to a diagnosis. Hybrid-capture next-generation sequencing inverts this logic entirely. By enriching microbial DNA from a patient sample and sequencing it comprehensively, NGS asks what organism is actually present, examining the full microbial landscape rather than hunting for a single predetermined target.
Eurofins Viracor's NeXGen™ Fungal/AFB assay illustrates the practical reach of this approach, detecting and identifying 534 fungal species and 154 acid-fast bacterial species from blood and bronchoalveolar lavage samples in a single run. Where traditional testing narrows possibilities through guesswork, this platform opens the field with genuine breadth — delivering species-level identification that supports precise, individualized treatment decisions.
Identifying a pathogen, however, is only part of the clinical picture. Understanding whether a patient's immune system can mount an effective response is equally critical. Complementary immune functional assays measuring pathogen-specific cellular responses for CMV, EBV, and BK virus give clinicians a second layer of insight — not just what infection is present, but how equipped the patient is to fight it. Together, these tools reflect a broader movement in infectious disease care: away from isolated data points and toward the kind of comprehensive, personalized understanding that transforms diagnostic uncertainty into a clear path forward.
A patient arrives at the hospital with fever, imaging that suggests infection, and lab work pointing toward inflammation. The symptoms could mean a dozen different things. Cultures come back negative. The standard tests—designed to hunt for specific pathogens one at a time—find nothing. The clinician suspects infection is happening, but the evidence remains frustratingly incomplete. This is the diagnostic dead end that next-generation sequencing is beginning to solve.
Infectious disease diagnosis often follows a predictable script. A patient presents with recognizable symptoms. A targeted test confirms the suspected culprit. Treatment begins. But for immunocompromised individuals, transplant recipients, cancer patients, and others vulnerable to opportunistic infections, the script breaks down. Their symptoms overlap with multiple conditions. Their imaging findings are ambiguous. Their cultures stay negative. Conventional molecular tests only identify organisms they were built to find—they ask a narrow question: "Is this specific pathogen present?" When the answer is no, or when no one thought to ask about the right organism in the first place, the clinician is left with suspicion but no actionable diagnosis.
Hybrid-capture next-generation sequencing flips that question. Instead of hunting for one pathogen at a time, NGS asks: "What organism is actually present?" Rather than searching for a single needle in a haystack, it examines the entire haystack at once. The technology uses targeted probes to enrich microbial DNA from a patient sample before sequencing, pulling out pathogen genetic material that might be present at very low levels, buried under the vast background of human DNA. This enrichment strategy allows clinicians to evaluate hundreds of potential infectious causes simultaneously—a fundamentally different approach to the diagnostic puzzle.
Eurofins Viracor's NeXGen™ platform exemplifies this shift. The NeXGen™ Fungal/AFB assay can detect and identify 534 different fungal species and 154 acid-fast bacterial species from blood and bronchoalveolar lavage samples. When a patient's symptoms are nonspecific, when traditional testing has failed, when a low-burden infection is suspected, or when multiple pathogens are under consideration, this breadth of coverage becomes invaluable. Rather than narrowing the diagnostic field through guesswork, clinicians can now see the microbial landscape with genuine clarity. The result is species-level identification that supports individualized treatment decisions—moving from a broad list of possibilities toward precision.
But pathogen identification alone tells only half the story. Equally important is understanding how a patient's immune system responds once an infection has been identified. Eurofins Viracor's inSIGHT™ immune functional assays measure pathogen-specific cellular immune responses for CMV, EBV, and BK virus, offering clinicians insight into whether a patient's body can actually mount an effective defense against the infection that has been found. Together, these tools address two critical clinical questions: What pathogen may be present, and how effectively can the patient respond to it? This complementary approach reflects a broader shift in infectious disease management toward personalization—away from isolated data points and toward comprehensive understanding.
The company's expertise in this space runs deep. With over four decades of diagnostic work in infectious disease, immunology, and allergy testing for immunocompromised and critical patients, Eurofins Viracor has built its reputation on serving transplant, infectious disease, oncology, and hematology specialists managing patients with complex diagnostic needs. The NeXGen™ portfolio represents one dimension of that commitment: helping clinicians transform uncertainty into clarity, suspicion into specificity, and diagnostic questions into actionable insights. As infectious disease management becomes increasingly personalized, clinicians need tools that deliver more than data—they need technologies capable of turning the frustrating diagnostic dead end into a clear path forward.
Citações Notáveis
Rather than searching for a single pathogen at a time, NGS technology allows clinicians to evaluate a much broader range of potential infectious causes simultaneously.— Eurofins Viracor on NGS diagnostic approach
Quer a matéria completa?
Leia o original em Future of Personal Health - ↗
Health & Medicine